Buch, Englisch, 620 Seiten, Format (B × H): 191 mm x 234 mm, Gewicht: 1247 g
Buch, Englisch, 620 Seiten, Format (B × H): 191 mm x 234 mm, Gewicht: 1247 g
ISBN: 978-0-12-820490-0
Verlag: Elsevier Science
Toxicological Evaluation of Electronic Nicotine Delivery Products?(ENDP) discusses the scientific basis for the toxicological assessment and evaluation of ENDPs. The book covers aerosol chemistry, in vitro and in vivo studies as well as clinical studies. It provides the basis for the evaluation of short and long term-effects, along with relative risks. It also examines the potential role of ENDPs in tobacco harm reduction and how they may reduce the risk of disease in smokers who switch to them.?This book is a comprehensive resource for toxicologists, health practitioners and public health professionals who want the scientific information necessary to assess the relative risk of ENDPs when compared with cigarette smoking and cessation.
Zielgruppe
<p>: Toxicologists (academia, regulatory authorities and industry); Public health professionals (academia, government)</p>
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Public Health, Gesundheitsmanagement, Gesundheitsökonomie, Gesundheitspolitik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
Weitere Infos & Material
1. Tobacco Harm Reduction 2. Electronic nicotine delivery devices (ENDS) 3. The scientific basis for the assessment of ENDS 4. Quantification of HPHC in ENDS aerosols 5. Aerosol physics and dynamics 6. Advanced analytical chemistry methods to characterize ENDS aerosols 7. Other species of toxicological concern 8. Impact of ENDS on indoor air quality 9. A systems-based approach to toxicity testing 10. Translational aspects of toxicity testing 11. Dosimetry and human-relevant exposure 12. Aerosol generation, exposure, and collection 13. Toxicological assessment in vitro 14. Toxicological assessment in vivo 15. Assessment of in vivo models of disease 16. Flavors and their toxicological assessment 17. A clinical strategy for ENDS testing 18. The disease risk reduction potential of ENDS 19. Residual risk associated to nicotine 20. Conclusion